Delta‐Like Homolog 2 Facilitates Malignancy of Hepatocellular Carcinoma via Activating EGFR/PKM2 Signaling Pathway
Molecular Carcinogenesis · 2025
DOI: 10.1002/mc.23836 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Carcinogenesis, 2025. Verfasst von Xiangye Liu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Jiangsu Key Laboratory of Immunity and Metabolism, Department of Pathogenic Biology and Immunology, Xuzhou Medical University, Xuzhou, Jiangsu Provin…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Membrane Proteins, ErbB Receptors. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: This work was supported by the National Natural Science Foundation of China (Grant No. 81802389 and 81972242), the Research Foundation of Xuzhou Medical Univer….
Abstract (Originalsprache)
Delta‐like homolog 2 (DLK2) plays a crucial role in adipogenesis, chondrogenic differentiation, and the progression of certain cancers. However, the key roles of DLK2 underlying the progression of hepatocellular carcinoma (HCC) remain ambiguous. In the current study, we demonstrate that DLK2 is upregulated in HCC, significantly correlated with clinicopathological variables and serves as an independent diagnostic marker. Functional assays reveal that DLK2 facilitates malignant progression of HCC in vitro and in vivo models. Mechanistically, DLK2 binds to EGFR resulting in its auto‐phosphorylation, which activates NF‐κB pathway leading to P65‐dependent transcriptional upregulation of PKM2. Furthermore, that elevates both enzyme‐dependent and ‐independent activities of PKM2 contributing to cancer proliferation and metastasis. In summary, our findings demonstrate a novel pro‐tumoral role and mechanism of DLK2 in the regulation of HCC malignant progression, suggesting its potential as a clinical diagnostic marker and therapeutic target.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Jiangsu Key Laboratory of Immunity and Metabolism, Department of Pathogenic Biology and Immunology, Xuzhou Medical University, Xuzhou, Jiangsu Province, People's Republic of China.
- Cancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu Province, People's Republic of China.
- Department of General Surgery, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu Province, People's Republic of China.
- School of Life Science, Xuzhou Medical University, Xuzhou, Jiangsu Province, People's Republic of China.
Förderung
- This work was supported by the National Natural Science Foundation of China (Grant No. 81802389 and 81972242), the Research Foundation of Xuzhou Medical Univer…
Zitieren
APA
Liu, X., Li, T., Wang, Y., Gao, X., Wang, F., Chen, Y., Wang, K., Luo, W., Kong, F., Kou, Y., You, H., Kong, D., Zhang, Q., & Tang, R. (2025). Delta‐Like Homolog 2 Facilitates Malignancy of Hepatocellular Carcinoma via Activating EGFR/PKM2 Signaling Pathway. Molecular Carcinogenesis. https://doi.org/10.1002/mc.23836
Vancouver
Liu X, Li T, Wang Y, Gao X, Wang F, Chen Y, et al. Delta‐Like Homolog 2 Facilitates Malignancy of Hepatocellular Carcinoma via Activating EGFR/PKM2 Signaling Pathway. Molecular Carcinogenesis. 2025. doi:10.1002/mc.23836
BibTeX
@article{Liu2025,
author = {Liu, Xiangye and Li, Tingting and Wang, Yuting and Gao, Xiaoge and Wang, Feitong and Chen, Yang and Wang, Kaisheng and Luo, Weiming and Kong, Fanyun and Kou, Yanbo and You, Hongjuan and Kong, Delong and Zhang, Qing and Tang, Renxian},
title = {Delta‐Like Homolog 2 Facilitates Malignancy of Hepatocellular Carcinoma via Activating EGFR/PKM2 Signaling Pathway},
journal = {Molecular Carcinogenesis},
year = {2025},
doi = {10.1002/mc.23836}
}
EUVIMED